Key terms
About ORIC
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ORIC news
Apr 15
4:17pm ET
Oric doses first patient in dose escalation portion of ORIC-114 trial
Apr 09
7:40am ET
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
Apr 08
8:16am ET
Oric Pharmaceuticals presents preclinical data on ORIC-944, ORIC-613
Mar 29
4:33pm ET
Oric Pharmaceuticals Bolsters Incentive Plan to Attract Talent
Mar 26
8:38pm ET
Oric Pharmaceuticals price target lowered to $18 from $19 at JPMorgan
Mar 21
6:27am ET
Oric Pharmaceuticals: Sustained Buy Rating Amid Strong Financials and Upcoming Catalysts
Mar 21
6:12am ET
Oric Pharmaceuticals price target raised to $21 from $15 at H.C. Wainwright
Mar 12
8:35am ET
Oric Pharmaceuticals price target raised to $17 from $14 at Oppenheimer
Mar 12
8:20am ET
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
Mar 12
6:49am ET
Oric Pharmaceuticals price target lowered to $25 from $27 at Baird
Mar 11
5:29pm ET
Oric Pharmaceuticals files automatic mixed securities shelf
Mar 11
4:07pm ET
Oric Pharmaceuticals reports Q4 EPS (49c), consensus (49c)
Mar 08
4:22pm ET
Oric Pharmaceuticals CEO Chacko sells 40,000 common shares
Mar 05
1:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 01
8:27am ET
Oric Pharmaceuticals price target raised to $20 from $12 at Wedbush
Mar 01
8:20am ET
Analysts Conflicted on These Healthcare Names: DENTSPLY SIRONA (XRAY), Xenon (XENE) and Oric Pharmaceuticals (ORIC)
Mar 01
7:48am ET
Oppenheimer Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)
Feb 23
7:21am ET
Oric Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Feb 23
6:07am ET
Oric Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Jan 26
4:59pm ET
Oric Pharmaceuticals files to sell 12.5M shares of common stock for holders
Jan 24
4:47pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
Jan 22
8:36am ET
Oric Pharmaceuticals to sell 12.5M shares at $10.00 in private placement
Jan 17
7:44am ET
JPMorgan ups Oric target, removes from Analyst Focus List
No recent press releases are available for ORIC
ORIC Financials
Key terms
Ad Feedback
ORIC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ORIC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
